MRNA climbs nearly 6% after upbeat Phase 3 melanoma vaccine results and strong technical momentum

Traders Union
All News
Stocks
Moderna surges 5.61% today on news

Highlights

Moderna announced positive Phase 3 results for its personalized mRNA melanoma vaccine developed with Merck, showing significant reduction in recurrence and metastasis.
The company received US regulatory approval for mFlusiva, an mRNA flu vaccine for adults aged 50 and over, and reported better than expected earnings on July 31.
Shares of Moderna last traded at $148.21, with technical readings showing continued upward momentum and an expected five-day range of $135.55 to $159.44.

Pipeline gains and positive earnings fuel investor optimism

Moderna reported a breakthrough with its personalized mRNA melanoma vaccine in partnership with Merck, as positive Phase 3 results showed meaningful prevention of melanoma recurrence and spread. The company also secured US regulatory approval for mFlusiva, its mRNA-based seasonal flu vaccine for adults aged 50 and over. Its recent earnings release on July 31 topped expectations, and participation in major healthcare conferences was announced for September 2026.

Anton Kharitonov, expert at Traders Union, cautions that Moderna’s recent gains are heavily reliant on headline-driven momentum. He notes persistent overbought signals across key technical indicators, with RSI and CCI readings flagging exhaustion. Despite regulatory milestones, he believes market sentiment may be overly optimistic given the potential for sharp profit-taking. Critical supports could be swiftly tested below $135.55 if bullish enthusiasm fades. Kharitonov warns, "Given current valuations and technical overextension, any disappointment may catalyze abrupt downside."

Viktoras Karapetjanc, expert at Traders Union, views Moderna’s position as structurally strong after its breakthrough melanoma vaccine and the recent US approval for mFlusiva. He notes that recent earnings outperformance and high-profile partnerships reinforce further optimism, with buyers clearly dominating trading flows. Karapetjanc points out that the bullish structure remains intact above $135.55, and the path is open for a breakout above $155.97. "The market offers multiple setups for further growth, with momentum and fundamentals both supporting an upward trajectory," he asserts.

Jainam Mehta, market strategist, sees the technical landscape turning constructive but notes that price has entered moderately overbought territory. He highlights the potential for a range-bound consolidation near current highs unless a breakout above $155.97 materializes. Given the backdrop of bullish news flow, Mehta suggests tactical trades could focus on breakout entries or short-term fades on spikes. "A clear surge above resistance would confirm continued strength, but traders should watch for reversals if momentum stalls," Mehta explains.

Overbought signals intensify as price nears key resistance

Moderna is trading above its short-, medium-, and long-term moving averages, with the MA-20 at $99.34, MA-50 at $78.33, and MA-200 at $52.34, confirming a robust bullish tilt on all timeframes. The immediate technical ceiling is found at $155.97, while today's high at $146.92 serves as near-term support. Additional trend confirmation comes from levels such as the Ichimoku Kijun at $114.66 and the longer-term moving averages, though these are less relevant for immediate support. Momentum indicators, including MACD and ADX, display ongoing buying strength. The RSI is at 64.11 and CCI at 65.87, reflecting moderately overbought conditions, while the Stochastic RSI reads neutral at 24.4. Bull/Bear Power stands strong at 20.1, indicating dominant buying activity during the session, but with overbought warnings flagged. Persistent intraday strength is evident near current highs, backed by intraday volatility of 6.39%. Most momentum signals align with the day's uptrend, but rising overbought indications warrant caution for potential short-term exhaustion.

Previously it was reported that analysts viewed Moderna's technical structure as bullish despite dilution concerns from a large convertible note offering. The latest clinical milestone and technical breakout reinforce this positive outlook, making the $155.97 resistance level a critical threshold for potential further upside in the coming sessions.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.